{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.2","upperLimit":"36.5","value":"30.8"},{"groupId":"OG001","lowerLimit":"28.9","upperLimit":"37.1","value":"33.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"322"},{"groupId":"OG001","value":"324"}],"units":"Participants"}],"description":"The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Velcade (bortezomib) 1.3 milligram/meter per square (mg/m\\^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.","id":"OG000","title":"Velcade (Bortezomib) Monotherapy"},{"description":"Velcade (bortezomib) 1.3 mg/m\\^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m\\^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.","id":"OG001","title":"Doxil/Caelyx Plus Velcade (Bortezomib)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 9 years and 5 months (From date of first participant randomization [20 December 2004] to cut-off date for final survival analysis (16 May 2014)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}